Arrowhead Pharmaceuticals, INC. 8-K Filing

Ticker: ARWR · Form: 8-K · Filed: Sep 11, 2025 · CIK: 879407

Sentiment: neutral

Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2025-09-11 07:31:06

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events On September 10, 2025, Arrowhead Pharmaceuticals, Inc. (the "Company" or the "Plaintiff") filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (the "Defendant") to declare that Ionis's United States Patent Number 9,593,333 ("the '333 patent") is invalid and/or not infringed by the Company's planned commercialization of investigational plozasiran. A copy of the complaint is attached hereto as Exhibit 99.1 (the "Complaint"). The Company intends to vigorously pursue its claims in this litigation.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this report except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, statements about our planned commercialization of investigational plozasiran and beliefs and expectations regarding the merit of the Ionis letter, the validity and enforceability of the 333 Patent, the Company's patent portfolio, and the Company's claims and lawsuit against the Defendant. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Complaint for Declaratory Judgment dated September 10, 2025 99.2 Press Release, dated September 11, 2025. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: September 11, 2025 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Daniel Apel Daniel Apel Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing